Comparison
BPC-157 vs TB-500: what is known, and why is neither approved?
Neither BPC-157 nor TB-500 is approved for human use in the US, and neither can be lawfully compounded today. BPC-157 is based on a fragment of a stomach protein; TB-500 is a fragment of thymosin beta-4. Almost all evidence for both comes from animal and lab studies, and FDA’s 2026 reviews found essentially no human safety data.
How do BPC-157 and TB-500 compare?
| Attribute | BPC-157 | TB-500 |
|---|---|---|
| Regulatory status | Research only · Not for human use | Research only · Not for human use |
| Human evidence | Animal & lab studies only | Animal & lab studies only |
| Comes as | Injection (unapproved), Oral capsule (unapproved) | Injection (unapproved) |
| How you get it | Not lawfully available for personal use. DiscoverMedica links to no seller. | Not lawfully available for personal use. DiscoverMedica links to no seller. |
| What it is | A 15-amino-acid synthetic peptide based on a fragment of a stomach protein | A short synthetic fragment of thymosin beta-4, a natural repair protein |
| Human dataFDA briefing, BPC-157FDA briefing, TB-500 | FDA found no studies giving it to people by the routes it is marketed for | FDA found no published case of it being given to patients, and no toxicity studies |
| FDA advisory vote, July 2026McDermott Will & Schulte | 8 to 6 to recommend a compounding route for ulcerative colitis, against FDA staff advice. Not binding | 8 to 6 to recommend a compounding route, against FDA staff advice. Not binding |
| Tested sportWADA 2026 Prohibited List (PDF mirror) | Prohibited | Prohibited |
| Key risksFDA briefing, BPC-157FDA briefing, TB-500 | Not made to drug standards, so identity, purity and sterility are unverified. FDA reviewers flagged immune reactions and poor characterization. It promotes blood vessel growth in animal studies, a theoretical concern with cancer. | Not made to drug standards. FDA flagged a potential for aggregation and immune reactions. The parent protein supports cell migration and blood vessel growth, a theoretical concern with cancer. |
| Listed prices | No lawful seller, so no price is listed. | No lawful seller, so no price is listed. |
Status, evidence, formats, routes and prices come from each compound’s page. Prices are the providers’ own listed starting prices, which may exclude a membership fee and change often; they are not DiscoverMedica’s prices.
What does the evidence say about BPC-157 and TB-500?
For both, almost everything comes from animals and cells. A 2025 systematic review of BPC-157 in orthopaedic sports medicine found 36 studies, 35 of them preclinical, and no clinical safety data. For TB-500, FDA’s 2026 review found no published human treatment data at all. HSS J 2025
FDA’s review also cites a lab study in which TB-500 itself did not speed wound closure, so findings for the full thymosin beta-4 protein may not apply to the fragment. FDA briefing, TB-500
A 2026 review for orthopaedic and sports medicine physicians says human orthopaedic data for thymosin beta-4 and TB-500 are lacking. Injectable peptide therapy
Why are BPC-157 and TB-500 not approved?
Approval requires evidence that a drug is safe and effective, and neither has been through controlled human trials. FDA’s reviewers found BPC-157 is not well characterized, testing for impurities was lacking, and it may carry a significant risk of immune reactions. FDA briefing, BPC-157
Both were on FDA’s Category 2 list of bulk substances that may present significant safety risks until FDA removed them in April 2026 and scheduled advisory committee meetings. Orrick
Could BPC-157 or TB-500 become legal to compound?
Possibly, but nothing is final. FDA’s advisory committee voted 8 to 6 for each in July 2026, against FDA staff recommendations. FDA still has to decide and complete rulemaking before either could be added to the list pharmacies compound from, so no lawful compounding route exists today. McDermott Will & Schulte
Meanwhile, FDA has sent warning letters to online sellers of these peptides that use “research use only” labels while making human-use claims. FDA warning letter
Which might suit whom: BPC-157 or TB-500?
Neither is lawfully available for personal use, and DiscoverMedica links to no seller of either. If you are considering them, these are better questions to take to a clinician:
- What evidence-based treatments, such as physical therapy, fit my injury, and what should I expect from each?
- Is there a clinical trial I could join?
- Given my history, including any cancer, what risks would an unapproved injectable carry for me?
- If FDA finalizes a compounding route, would it be appropriate for me?
DiscoverMedica does not recommend one over the other. Only a licensed clinician who knows your history can decide.
Looking for a lawful option?
See every compound in fitness, strength & recovery with its US status, evidence and risks. Only a licensed clinician who knows your history can decide what fits.
BPC-157 vs TB-500: questions, answered
Is BPC-157 or TB-500 legal in the US?
Neither is FDA-approved for human use, and neither is on the list of ingredients pharmacies may compound from, so there is no lawful route for personal use today. FDA has sent warning letters to companies selling them for human use under “research use only” labels.
Which is safer, BPC-157 or TB-500?
Neither has been shown safe in people. FDA found essentially no human safety data for either, flagged a risk of immune reactions for both, and products sold online are not made to drug standards, so identity, purity and sterility are unverified.
Is TB-500 the same as thymosin beta-4?
No. Thymosin beta-4 is a natural repair protein; TB-500 is a short synthetic fragment of it. FDA’s 2026 review cites a lab study in which the fragment did not speed wound closure, so findings for the full protein may not apply to TB-500. FDA found no published case of TB-500 being given to patients.
Are BPC-157 and TB-500 banned in sport?
Yes. BPC-157 is named on WADA’s 2026 list of non-approved substances, and the list names thymosin beta-4 and its derivatives, including TB-500, as prohibited.
Can a telehealth provider prescribe BPC-157 or TB-500?
Not lawfully today. With no FDA approval and no place on the compounding list, a licensed telehealth provider has no approved or compounded product to prescribe. If a site offers either, treat that as a warning sign.
Sources
- FDA briefing document for the July 2026 advisory committee: BPC-157
- FDA briefing document for the July 2026 advisory committee: TB-500
- Emerging use of BPC-157 in orthopaedic sports medicine: systematic review (HSS J 2025)
- Injectable peptide therapy: a primer for orthopaedic and sports medicine physicians (Am J Sports Med 2026)
- McDermott Will & Schulte: PCAC backs majority of peptides in two-day public meeting (July 2026)
- FDA: Pharmacy Compounding Advisory Committee, July 23-24, 2026
- Orrick: FDA removes 12 peptides from Category 2 and schedules PCAC meetings (Apr 2026)
- FDA: Bulk drug substances that may present significant safety risks (Category 2)
- FDA warning letter: Peptide Partners (Aug 24, 2026)
- USADA: BPC-157, prohibited peptide
- WADA 2026 Prohibited List (PDF mirror)
- PubChem: TB-500 (CID 62707662)
Last reviewed October 7, 2026. Every source above was checked on or before that date. Educational information only, not medical advice; it does not replace a conversation with a licensed clinician. DiscoverMedica does not employ clinicians.